MRK 10-K Analysis: The Cash Flow Crisis Behind Merck's Earnings Growth

Merck & Co., the $65 billion pharmaceutical company behind Keytruda — the world's best-selling drug at $31.7 billion — reported 8% earnings growth in FY2025 while tripling its share buybacks to $5.1 billion. The company raised its dividend for the 15th consecutive year. Analysts focused on Keytruda's continued 7% revenue momentum and the strong Winrevair launch. By most income statement measures, Merck had a good year.

The 10-K tells a different story. Free cash flow collapsed 32% to $12.4 billion. Cash conversion — the ratio of operating cash flow to net income — fell below 1.0x for the first time, meaning Merck collected less cash than it reported in earnings. Working capital absorbed $4.8 billion, and the company issued $14 billion in new debt that halved its operating cash flow-to-debt coverage ratio from 0.6:1 to 0.3:1.

This isn't a story about a bad quarter. It's about a company funding both its post-Keytruda transformation and aggressive shareholder returns from the same debt-funded pool, while the cash generation underneath deteriorates. The question the filing forces: is Merck paying investors from its cash register or its credit line — and does the distinction matter when 49% of its revenue faces a triple cliff in 2028-2029?

The Cash Flow Mirage

Merck's FY2025 income statement shows a company in solid health: revenue grew 1.3% to $65.0 billion, operating margin expanded 250 basis points to 34.0%, and GAAP EPS rose 8% to $7.28. Look at the cash flow statement, and the picture inverts. Operating cash flow fell 23% to $16.5 billion. Free cash flow — the cash left after capital expenditures — declined 32% to $12.4 billion, producing a cash conversion ratio of 0.90x. For every dollar of earnings Merck reported, it collected ninety cents in cash. A year earlier, it collected $1.25.

The divergence has three drivers. First, working capital consumed $4.8 billion — a 47% surge driven by accounts receivable growth ($1.5 billion from Keytruda and Winrevair sales timing), rising other current assets ($1.8 billion), and inventory adjustments. Second, capital expenditures rose 22% to $4.1 billion as Merck built manufacturing capacity for pipeline products. Third, higher inventory write-downs, primarily from unsold vaccines, absorbed cash that never appeared on the income statement.

The earnings quality deterioration goes beyond cash flow. Management's non-GAAP EPS of $8.98 exceeded GAAP EPS of $7.28 by $1.70 per share — nearly double the $0.91 gap a year earlier. Non-GAAP earnings grew 17.4% while GAAP grew 8.0%, meaning management's preferred metric advances at 2.2 times the rate of reported earnings. The gap is driven by $2.6 billion in restructuring charges (tripling year-over-year) and $3.0 billion in acquisition-related costs. Management labels these add-backs "non-recurring," but the two overlapping restructuring programs span 2024 through 2031 — seven years of charges Merck systematically excludes from the number it wants investors to use.

"The gross margin decline was primarily due to the negative impacts of higher restructuring costs (primarily related to the accelerated depreciation of manufacturing lines at two sites under the 2025 Restructuring Program), higher inventory write-downs (primarily vaccines), increased amortization of intangibles, and the recognition of fair value step-up of inventories related to the Verona Pharma acquisition."

Meanwhile, operating margin expanded 250 basis points despite gross margin contracting 150 basis points. The explanation: business development R&D charges fell $2.9 billion year-over-year as large one-time acquisition costs from 2024 didn't repeat. The operating leverage investors see comes from cost reductions and lower one-time charges — not from the top line growing into a fixed cost base. Merck's free cash flow collapsed 31.7% to $12.4 billion in FY2025 despite revenue growing 1.3%, as working capital absorbed $4.8 billion and cash conversion fell below 1.0x for the first time.

The Triple Cliff

Standard patent cliff analysis models a single event: loss of exclusivity leads to biosimilar competition, which erodes revenue over 3-5 years. Merck's Keytruda faces something without precedent — three simultaneous pricing constraints converging on a single product that generates 49% of total company sales.

"In particular, in the aggregate, in 2025, sales of Keytruda represented 49% of the Company's total sales."

The first constraint is conventional: Keytruda's core US patent expires in 2028, opening the door to biosimilar competition. The second is the Inflation Reduction Act — Merck expects Keytruda to be selected for government price negotiation in 2027, with the negotiated price effective January 1, 2029. The third, disclosed for the first time in this 10-K, is the Most Favored Nation Agreement signed December 2025. Under the MFN, Merck must provide key products at affordable prices for eligible patients and — critically — subject future product launches to MFN pricing that references foreign country prices. This constrains not just Keytruda's current revenue but the pricing power of every replacement drug Merck launches to fill the gap.

The geographic concentration shift makes the cliff steeper. US revenue grew from 50% to 56.2% of Merck's total in FY2025, driven by international weakness (China down 65%, Japan down 17%). The US is the market most exposed to both IRA pricing and the MFN Agreement — meaning Merck's revenue base is increasingly concentrated in the geography with the most pricing constraints.

The Januvia precedent is instructive. Merck's own filing discloses that Medicaid rebates on Januvia, Janumet, and Janumet XR already exceeded Medicaid sales in 2024 — meaning Merck paid more in government rebates than it received on those sales. When government pricing pushes rebates above 100% of sales on one product, the economics of that product become actively destructive. Keytruda isn't there yet, but the mechanism is established. Merck faces a triple cliff on Keytruda — patent expiry in 2028, IRA government price-setting effective 2029, and the MFN Agreement signed December 2025 — threatening 49% of the company's total sales within a single product.

The Replacement Math

Merck's pipeline is producing. Winrevair generated $1.4 billion in its first full year treating pulmonary arterial hypertension. Capvaxive, the new pneumococcal vaccine, delivered $759 million. Prevymis ($978 million), Welireg ($716 million), and Reblozyl ($525 million) are all growing. Collectively, these growth products generated $4.4 billion in FY2025 — genuine revenue from genuine products. The pipeline works.

But the replacement velocity does not. While growth products added $4.4 billion, declining products lost $3.9 billion: Gardasil fell $3.4 billion (driven by China's 65% collapse) and Lagevrio declined $584 million. The net revenue displacement across Merck's entire portfolio was just $444 million — on a $65 billion revenue base. For a company that needs to replace $31.7 billion in Keytruda revenue over the next several years, net displacement under $500 million signals that the pipeline is running to stand still.

"Beginning in mid-2024, the Company observed a significant decline in shipments from its distributor and commercialization partner in China."

The Gardasil picture is more nuanced than headlines suggest. US Gardasil actually grew 8.9% to $2.6 billion, driven by higher pricing and favorable CDC purchasing. The crisis is entirely international: China revenue collapsed 64.7% in one year and 71.5% over two years, from $6.8 billion to $1.9 billion. The filing's shift to "persistent lower demand" language — from earlier "declining demand" framing — signals management now treats this as structural, not cyclical. The US franchise is healthy; the impairment is geographically contained but massive.

Adding pressure, Bridion ($1.8 billion in FY2025) loses US exclusivity in July 2026. The filing warns of a "significant and rapid decline in U.S. sales" post-expiry — another revenue headwind arriving before the main Keytruda cliff even begins.

The most instructive comparison is AbbVie's Humira cliff. When Humira's biosimilar competition began, AbbVie had Skyrizi and Rinvoq already generating $10+ billion combined — a replacement ratio of 0.47x (replacement revenue divided by product at risk). Merck's current replacement ratio is 0.14x ($4.4 billion against $31.7 billion), which is 3.4 times worse than AbbVie's starting position. AbbVie grew revenue 8.6% during its cliff; Merck is growing 1.3% before its cliff even starts. And AbbVie faced only biosimilar competition — Merck faces the triple cliff.

To match AbbVie's replacement ratio of 0.47x at cliff entry, Merck needs $14.9 billion in pipeline revenue — a 3.4x increase from current levels within 2-3 years. Merck's pipeline replacement ratio of 0.14x — $4.4 billion in new products against $31.7 billion in Keytruda revenue — is 3.4 times worse than AbbVie's 0.47x position when Humira's biosimilar cliff began, representing a historically unprecedented scaling challenge for a single pharmaceutical company.

The Leverage Gambit

Merck's strategic response to the approaching cliff is audacious: transform the company on three fronts simultaneously. Acquire growth ($19.6 billion on Verona Pharma and Cidara). Restructure operations ($7 billion spanning 2024-2031 to retool manufacturing for post-Keytruda products). And accelerate shareholder returns ($13.3 billion, up 44% year-over-year). All three draw from the same capital pool — and that pool is increasingly funded by debt.

"In December 2025, the Company issued $8.0 billion aggregate principal amount of senior unsecured notes... In September 2025, the Company issued $6.0 billion aggregate principal amount of senior unsecured notes."

The $14 billion in new debt pushed total debt up 33% in a single year, from $37.1 billion to $49.3 billion. Net debt surged 48% to $34.6 billion. The debt-to-equity ratio rose from 0.80x to 0.94x. Most telling, the operating cash flow-to-debt coverage ratio halved from 0.6:1 to 0.3:1 — Merck's operating cash flow now covers less than one-third of its total debt, down from nearly two-thirds a year ago.

The capital return numbers underscore the paradox. Merck returned $13.3 billion to shareholders — 108% of its free cash flow. Buybacks alone tripled from $1.3 billion to $5.1 billion under a new $10 billion authorization. This means Merck returned more cash to shareholders than it generated from operations, funding the difference from the same debt proceeds earmarked for acquisitions. The 289% buyback increase occurred in the same year that free cash flow fell 32% and the company added $14 billion in obligations.

Core R&D tells a more constructive story. Merck Research Laboratories spending increased 6.9% to $10.8 billion, even as the headline R&D figure declined 12%. The difference: lower one-time business development charges (acquisition-related R&D like EyeBio in 2024) compressed the total, masking a genuine increase in pipeline investment. Animal Health ($6.4 billion, +8.1% with margins improving to 33.5%) provides the only organic growth diversification that doesn't depend on the pharmaceutical pipeline delivering against the cliff.

Pre-launch inventory of $5.4 billion, classified in Other Assets, signals management confidence in near-term pipeline approvals. Combined with on-balance-sheet inventory of $6.7 billion, Merck carries $12.1 billion in total inventory exposure. If pipeline drugs underperform, this creates write-down risk. If they succeed, the advance manufacturing preparation accelerates commercialization. Merck issued $14 billion in new debt in FY2025 to fund acquisitions while simultaneously returning $13.3 billion to shareholders — 108% of free cash flow — halving its operating cash flow-to-debt ratio from 0.6:1 to 0.3:1.

What to Watch

At $105.26, Merck trades at 14.4x trailing earnings — a 35-40% discount to large-cap pharma peers (JNJ 18.7x, ABT 33.6x). The multiple implies 0-2% annual revenue growth, and the filing delivered exactly +1.3%. By this measure, the market has the Keytruda cliff roughly priced in.

But the filing reveals three layers of risk the P/E doesn't fully capture. The triple cliff (patent + IRA + MFN) is steeper than a standard patent expiry. The replacement ratio (0.14x) is 3.4 times worse than AbbVie's proven cliff-navigation benchmark. And the leverage cost of the replacement strategy — $14 billion in new debt, OCF/debt coverage halved — adds financial risk on top of the revenue risk. Merck is funding both its transformation and its shareholder returns from the credit line, not the cash register. That distinction matters when the cliff arrives.

The filing supports the thesis that Merck's operating business remains formidable — 74.8% gross margins, 20.7% ROIC, a growing Animal Health segment, and genuinely productive pipeline launches. But it complicates the thesis that the 14.4x multiple adequately prices the risk, because it doesn't account for the leverage layer or the MFN constraint on replacement product pricing.

Track these metrics in 2026:

• Q1-Q2 2026 working capital change: If working capital reverses by $3 billion or more, FCF snaps back toward $16 billion and the cash conversion crisis was transitory. If absorption continues above $2 billion, it's structural.
• Bridion Q3 2026 revenue: Post-July exclusivity loss. If quarterly revenue holds above $400 million, biosimilar penetration is slower than expected. Below $250 million, the headwind exceeds models.
• Keytruda Qlex quarterly revenue: Currently at $40 million for FY2025 (0.13% of franchise). Management targets 30-40% conversion by 2028. Q1-Q2 2026 must show sequential growth above $80 million quarterly for the lifecycle extension thesis to remain credible. Below $30 million signals physician resistance.
• Pipeline revenue run rate: Watch whether the $4.4 billion in growth products approaches $7-8 billion annualized by year-end 2026. This pace would put Merck on track toward the 0.47x replacement ratio AbbVie achieved.
• OCF/debt ratio: Must stabilize above 0.3:1. Further deterioration toward 0.2:1 would signal a balance sheet that constrains strategic flexibility precisely when flexibility is most needed.

Frequently Asked Questions

How much of Merck's revenue depends on Keytruda?

Keytruda generated $31.7 billion in FY2025, representing 49% of Merck's total sales according to the company's own 10-K risk disclosure. Including the subcutaneous Keytruda Qlex formulation ($40 million), the franchise accounted for 48.7% of total revenue ($65.0 billion). This is extreme single-product concentration — AbbVie's largest product (Skyrizi at ~$15.2 billion) represents roughly 25% of its revenue, a materially more diversified position.

When does Keytruda's patent expire, and what other pricing constraints does it face?

Keytruda's core US patent expires in 2028, opening the door to biosimilar competition. The 10-K reveals two additional pricing constraints creating a triple cliff: IRA government price-setting (Merck expects Keytruda to be selected in 2027 with the government-negotiated price effective January 1, 2029) and the MFN Agreement signed December 2025, which subjects key products to affordable pricing requirements and references foreign pricing. No other major pharmaceutical product simultaneously faces patent loss, government price-setting, and MFN constraints.

Why did Merck's free cash flow decline so significantly in FY2025?

Free cash flow fell 31.7% from $18.1 billion to $12.4 billion despite revenue growing 1.3%. The decline had three drivers: operating cash flow fell 23.3% to $16.5 billion, primarily from a $4.8 billion working capital surge driven by accounts receivable growth ($1.5 billion), inventory changes, and rising other current assets; capital expenditures increased 22% to $4.1 billion; and higher inventory write-downs, primarily vaccines, absorbed cash. Cash conversion (OCF/NI) fell from 1.25x to 0.90x.

Is Merck's dividend safe?

Merck paid $8.25 billion in dividends in FY2025 (3.12% yield), representing 45.2% of net income and 66.8% of free cash flow. Including buybacks ($5.1 billion), total capital returns of $13.3 billion exceeded free cash flow by 8%. Merck funded the gap partly through debt. The dividend is covered for 2026-2027, but the post-2028 outlook depends entirely on pipeline replacement velocity and whether the triple cliff compresses both earnings and cash flow simultaneously.

How does Merck's Keytruda cliff compare to AbbVie's Humira cliff?

AbbVie's Humira peaked at approximately $21.2 billion before biosimilar competition began. AbbVie navigated this because Skyrizi and Rinvoq were already generating $10+ billion combined — a replacement ratio of about 0.47x. Merck's pipeline products total $4.4 billion against Keytruda's $31.7 billion — a ratio of only 0.14x, which is 3.4x worse. Additionally, AbbVie faced only biosimilar competition on Humira, while Merck faces a triple cliff of patent expiry, IRA pricing, and MFN constraints on a product 50% larger than Humira at peak.

What happened to Gardasil sales, and is the decline permanent?

Gardasil total sales fell 39% to $5.2 billion in FY2025. The decline is entirely international — US Gardasil actually grew 8.9% to $2.6 billion. International Gardasil collapsed 57.9%, overwhelmingly driven by China (revenue down 64.7% from $5.5 billion to $1.9 billion, and down 71.5% over two years from $6.8 billion). The filing's shift to "persistent lower demand" language indicates management now views the China weakness as structural, not cyclical.

How much debt did Merck take on in FY2025?

Merck issued $14.0 billion in new senior unsecured notes: $6.0 billion in September 2025 (to fund the Verona Pharma acquisition) and $8.0 billion in December 2025 (to fund the Cidara acquisition). Total debt surged 33% from $37.1 billion to $49.3 billion. Net debt rose 48% to $34.6 billion. The OCF-to-debt ratio halved from 0.6:1 to 0.3:1, meaning operating cash flow now covers less than one-third of total debt.

What is Merck's pipeline beyond Keytruda?

Merck's growth pipeline generated $4.4 billion in FY2025: Winrevair ($1.4 billion, PAH treatment), Capvaxive ($759 million, pneumococcal vaccine), Prevymis ($978 million, antiviral), Welireg ($716 million, oncology), and Reblozyl ($525 million, hematology). Core R&D (MRL) spending increased 6.9% to $10.8 billion. The headline -12% R&D decline was entirely driven by lower one-time business development charges, not reduced pipeline investment. Animal Health ($6.4 billion, +8.1%) provides stable diversification.

Why is Merck's P/E ratio so much lower than peers?

Merck trades at 14.4x trailing earnings versus JNJ 18.7x and ABT 33.6x. The discount reflects Keytruda cliff risk. However, the discount may be insufficient because: the triple cliff is steeper than a standard patent expiry; the replacement ratio (0.14x) is 3.4x worse than AbbVie's starting position; the leverage cost ($14 billion in new debt, OCF/debt halved) adds financial risk beyond revenue risk; and the cash generation crisis (FCF -32%) means less flexibility than the P/E implies.

What is the MFN Agreement and how does it affect Merck's future?

In December 2025, Merck entered the Most Favored Nation Agreement with the US government. The agreement requires key products at affordable prices for eligible patients and — most significant for long-term investors — subjects future product launches to MFN pricing referencing foreign countries. For a company whose thesis depends on pipeline drugs generating premium revenue to replace $31.7 billion in Keytruda, constrained launch pricing fundamentally narrows the revenue trajectory.

How should investors interpret the growing GAAP-to-Non-GAAP gap?

Non-GAAP EPS ($8.98) exceeded GAAP EPS ($7.28) by $1.70 per share in FY2025, nearly double the $0.91 gap in FY2024. Non-GAAP EPS grew 17.4% versus 8.0% for GAAP. The widening gap is driven by restructuring charges tripling to $2,551 million and acquisition costs of $3,007 million. The two overlapping restructuring programs span 2024-2031 — roughly seven years of charges management labels "non-recurring." When a company systematically excludes costs that persist for nearly a decade, the non-GAAP metric increasingly diverges from economic reality.

What is Keytruda Qlex and can it extend the franchise?

Keytruda Qlex is the subcutaneous formulation of Keytruda, approved by the FDA in September 2025. In its first partial year, Qlex generated only $40 million — 0.13% of the $31.7 billion Keytruda franchise. Management targets 30-40% conversion by 2028. Subcutaneous formulations can extend franchise life by maintaining market share against biosimilars that replicate only the IV formulation. At the current trajectory, conversion is below typical subcutaneous adoption curves. If Q1 2026 Qlex exceeds $80 million quarterly, the lifecycle extension thesis strengthens. Below $30 million, it weakens materially.

Methodology

Data Sources

This analysis uses data from Merck & Co.'s FY2025 10-K filing (filed 2026-02-24), accessed through SEC EDGAR and MetricDuck's filing text extraction pipeline. Financial metrics were calculated using MetricDuck's automated metrics processor, which extracts 194+ standardized metrics from XBRL-tagged SEC filings. Peer comparison data (ABBV, JNJ, ABT) was sourced from the same pipeline using each company's most recent annual filing. All filing quotes are verbatim from the source document.

Limitations

• Forward-looking projections are directional, not precise. Predictions about Bridion's post-cliff trajectory, working capital reversals, and Qlex adoption use historical biosimilar and subcutaneous conversion benchmarks but cannot account for product-specific competitive dynamics or formulary decisions.
• The AbbVie Humira cliff comparison is imperfect. Humira involved a single pricing event (biosimilar competition) in immunology. Merck's triple cliff is unprecedented, making the calibration approximate. AbbVie's replacement products were in different therapeutic categories than Humira, while Merck's replacements span oncology, vaccines, and cardiology.
• MFN Agreement scope is partially undisclosed. The exact pricing reference basket, discount formulas, and product coverage list are not fully disclosed in the 10-K. The analysis assumes broad constraint on future launch pricing, which may overstate impact if the agreement applies only to specific products.
• Working capital analysis lacks full inventory decomposition. The filing discloses "higher inventory write-downs (primarily vaccines)" but does not separate vaccine from pharmaceutical inventories on the balance sheet. The $4.8 billion working capital surge attribution is partly inferred from qualitative disclosures.
• ONC (BeOne Medicines) excluded from peer comparison. Originally listed as a peer, ONC is a Chinese biotech with extreme growth/valuation characteristics that distort comparison against large-cap diversified pharma. ABBV, JNJ, and ABT provide more meaningful benchmarks.

Disclaimer:

This analysis is for informational purposes only and does not constitute investment advice. The author does not hold positions in MRK, ABBV, JNJ, or ABT. Past performance and current metrics do not guarantee future results. All data is derived from public SEC filings and may contain errors or omissions from the automated extraction process.